Mengmeng Li

发表

Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma

Minghui Ge, Tingting Sun, Chuang Qi, 2022, Journal of Cancer Research and Clinical Oncology.

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis

N. Luo, Y. Qi, Mengmeng Li, 2021, Medicine.

Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations

Jie Ma, Yongjun Guo, Junnan Feng, 2022, Frontiers in Oncology.

The First Case Report of a Patient With Oligodendroglioma Harboring CHEK2 Germline Mutation

Xueen Li, H. Xue, N. Luo, 2022, Frontiers in Genetics.

Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion

Guo-Fang Liu, N. Luo, Binbin Liang, 2022, Medicine.

Molecular genomic landscape of pediatric solid tumors in Chinese patients: implications for clinical significance

Chuanwei Wang, Tingting Sun, Gang Li, 2023, Journal of Cancer Research and Clinical Oncology.

Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma

Xiaoya Feng, N. Luo, Y. Qi, 2022, Journal of Cancer Research and Clinical Oncology.

Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations

Chao Han, Chengwei Wang, Xuan Ding, 2022, Journal of Cancer Research and Clinical Oncology.

Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma

Minghui Ge, Tingting Sun, Chuang Qi, 2022, Journal of Cancer Research and Clinical Oncology.

Case report: Epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib

Chunhua Wei, Chao Shi, Mengmeng Li, 2023, Frontiers in Oncology.